Universal voluntary testing and treatment for prevention of HIV transmission

JAMA

Volumn 301, Issue 22, 2009, Pages 2380-2382

  Dieffenbach, Carl W ^a   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DENIAL; HEALTH CARE SYSTEM; HEALTH INSURANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMELESSNESS; HUMAN IMMUNODEFICIENCY VIRUS; MENTAL DISEASE; NOTE; PRIORITY JOURNAL; SCREENING; SUBSTANCE ABUSE; VIRUS LOAD; VIRUS TRANSMISSION; ANTIVIRAL RESISTANCE; ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MASS SCREENING; RESEARCH; SERODIAGNOSIS; THEORETICAL MODEL;

AIDS SERODIAGNOSIS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, VIRAL; HEALTH POLICY; HIV INFECTIONS; HUMANS; MASS SCREENING; MODELS, THEORETICAL; RESEARCH;

EID: 67049096181     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.828     Document Type: Note

References (14)

1. AIDSinfo Web page. http://www.aidsinfo.nih.gov/Guidelines/. Accessibility verified May 1, 2009.
2. Quinn TC, Wawer MJ, Sewankambo N, et al; Rakai Project Study Group. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342(13):921-929.
3. Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis. 2002;2(8):487-493. (Pubitemid 34826854)
4. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48-57.
5. Branson BM, Handsfield HH, Lampe MA, et al; Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1-17.
6. Pinkerton SD. Probability of HIV transmission during acute infection in Rakai, Uganda. AIDS Behav. 2008;12(5):677-684.
7. The CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection: the CASCADE Collaboration: Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet. 2000;355 (9210):1158-1159.
8. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS. 2008;22(8):973-981. (Pubitemid 351652248)
9. Castilla J, Del Romero J, Hernando V, Marincovich B, Garcia S, Rodriguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr. 2005;40(1):96-101. (Pubitemid 41233212)
10. Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet. 2008;372 (9635):314-320. (Pubitemid 352020440)
11. Vernazza P, Hirschel B, Bernasconi E, Flepp M. Les personnes seropositives ne souff rant d'aucune autre MST et suivant un traitment antiretroviral efficace ne transmettent pas le VIH par voie sexuelle. Bull Médecins Suisses. 2008;89:165-169.
12. Violari A, Cotton MF, Gibb DM, et al; CHER Study Team. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359 (21):2233-2244.
13. El-Sadr WM, Lundgren JD, Neaton JD, et al; Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283-2296.
14. Kitahata MM, Gange SJ, Abraham AG, et al; NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815-1826.